Lmr Partners LLP Apellis Pharmaceuticals, Inc. Call Options Transaction History

Lmr Partners LLP

  • $10.9 Billion
  • Q3 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Feb 14, 2024
SELL
$37.14 - $64.82 $5.03 Million - $8.78 Million
-135,400 Reduced 74.35%
46,700 $2.8 Million
Q3 2023

Nov 14, 2023
BUY
$23.65 - $89.22 $4.26 Million - $16.1 Million
180,100 Added 9005.0%
182,100 $6.93 Million
Q2 2023

Aug 14, 2023
BUY
$76.68 - $93.31 $153,360 - $186,620
2,000 New
2,000 $182,000

Others Institutions Holding APLS

# of Institutions
308
Shares Held
115M
Call Options Held
3.85M
Put Options Held
1.09M
View Full List

About Apellis Pharmaceuticals, Inc.

APLS Quotes by TradingView
  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.64B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Lmr Partners LLP Portfolio

Follow Lmr Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Lmr Partners LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email